Clinical trials: Schizophrenia(Acute)
Schizophrenia
Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients.
- Trial name
- QUENCH (NCT00779506)
- Testing
- Quetiapine Fumarate XR
- Where
- 7 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- AstraZeneca
Psychotic Disorders
A Closed Unit Incorporating Soteria Elements Versus a Conventional Closed Psychiatric Ward
This prospective study compares two models of inpatient psychiatric care for adults experiencing an acute psychotic episode of moderate to severe intensity that requires admission to a closed psychiatric setting.
- Trial name
- CSCW (NCT07836348)
- Testing
- Inpatient Care in a Closed Unit Incorporating Soteria Elements, Conventional Closed Psychiatric Inpatient Care
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Jerusalem Mental Health Center
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
There is a substantial need for enhancing the efficacy and effectiveness of Veterans Health Administration (VHA) inpatient services for psychosis and tailoring them to support recovery.
- Trial name
- ACT-IP (NCT01981356)
- Testing
- Acceptance and Commitment Therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Extrapyramidal Syndrome
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00331825
- Testing
- Risperidone and Olanzapine
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Schizophrenia
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up.
- Trial name
- NCT00404573
- Testing
- RGH-188
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Forest Laboratories
Schizophrenia
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
The purpose of this study is to assess the effectiveness, safety and tolerability of flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics and with acute…
- Trial name
- NCT01685931
- Testing
- Paliperidone Palmitate
- Where
- 17 sites in China
- Volunteers
- 617 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment sessions, parallel-group study. After screening period, eligible subjects will be entered 5 days treatment session I to compare the efficacy…
- Trial name
- NCT00859872
- Testing
- risperidone oral solution, haloperidol
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Central South University
Schizophrenia
A Study of LY2140023 in Patients With Schizophrenia
The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
- Trial name
- NCT01307800
- Testing
- LY2140023
- Where
- 13 sites in United States, Mexico and 3 more
- Volunteers
- 567 people
- Sponsor
- Denovo Biopharma LLC
Mental Health Issues, Bipolar Disorder
Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma
This study will use a systematic music therapy intervention on patients with mental illness trying to help them with their internalized stigma.
- Conditions
- Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05723328
- Testing
- Group Music Therapy Advocacy Recording Intervention (MTAR)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Hackensack Meridian Health
Schizophrenia, Schizoaffective Disorder
Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms
As of late Integrated Care Pathways (ICPs) have been shown to improve quality of care in the medical field with special attention given to mental health in particular.
- Trial name
- LLS-ICP (NCT02529163)
- Testing
- Late-life Schizophrenia ICP, Treatment as Usual
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04092686
- Testing
- SEP-363856 75mg, SEP-363856 100mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 464 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.
- Trial name
- NCT00954122
- Testing
- Quetiapine XR (Seroquel XR)
- Where
- 2 sites in Malaysia
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Amisulpride in Schizophrenic Acute Phase Patients
To collect the safety and response of using Amisulpride in acute schizophrenic patients
- Trial name
- ASAP (NCT00436371)
- Testing
- Amisulpride
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Sanofi